BUZZ-BridgeBio shares rise as FDA initiates priority review for dwarfism drug
路透社2026/10/06 12:17On October 6th, shares of pharmaceutical company BridgeBio Pharma (BBIO.O) rose 2.5% in pre-market trading to $67.80. The company announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its application seeking approval for the investigational oral drug infigratinib for the treatment of children with achondroplasia, the most common type of dwarfism. The FDA has set a target decision date of February 4, 2027. The application is based on a late-stage clinical trial that met both primary and key secondary endpoints; children treated with infigratinib experienced an adjusted annual growth velocity 1.74 centimeters greater than those given placebo. The drug also improved arm span and body proportions in children under eight years old. No serious adverse events or discontinuations related to the drug were reported. BridgeBio plans to apply for European approval in the fourth quarter of 2026. As of the close of the previous trading day, BBIO shares are down 13.5% year-to-date. (For the convenience of non-English speakers, Reuters has automated this report into several other languages. Because automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of automated translation, which is provided for readers’ convenience only. Reuters accepts no liability for any damages or losses arising from the use of automated translation.)
October 6 - ** The share price of pharmaceutical company BridgeBio Pharma (BBIO.O) rose 2.5% to $67.80 in pre-market trading
** The company announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its application seeking approval for the experimental oral drug infigratinib for the treatment of children with achondroplasia (the most common type of dwarfism)
** The FDA has set February 4, 2027, as the target date for a decision
** The application is based on a late-stage clinical study that met both its primary and key secondary endpoints; children treated with infigratinib had an annual growth rate (adjusted) 1.74 cm faster than those on placebo
** The drug also improved arm span and body proportion in children under 8 years old; no serious adverse events related to the drug or treatment-related discontinuations were reported
** BridgeBio plans to apply for European approval in the fourth quarter of 2026
** As of the close of the previous trading day, BBIO shares had fallen 13.5% so far this year
(To facilitate non-native English speakers, Reuters has automatically translated its reports into several other languages. As automated translations may contain errors or lack the needed context, Reuters does not guarantee the accuracy of translated texts and provides them solely for the convenience of readers. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Reality of AI Agentic Payments in 2026
Exchange-Traded Funds Mixed, US Equities Rise After Midday
01:09 PM EDT, 10/06/2026 (MT Newswires) -- Broad Market Indicators Broad-market exchange-traded fund IWM fell and IVV edged higher. Actively traded Invesco QQQ Trust (QQQ) added 0.7%. US equity indexes rose as big-tech names helped the S&P 500 and the Nasdaq Composite hit fresh all-time highs intraday amid declining government bond yields and crude oil. Energy IShares US Energy ETF (IYE) and the State Street Energy Select Sector SPDR (XLE) were each up about 0.8%. Technology The State Street Technology Select Sector SPDR ETF (XLK) gained 0.8%; iShares US Technology ETF (IYW) added 0.7%, and iShares Expanded Tech Sector ETF (IGM) was 0.8% higher. The State Street SPDR S&P Semiconductor (XSD) climbed 1.4%, and iShares Semiconductor (SOXX) rose 0.6%. Financial The State Street Financial Select Sector SPDR (XLF) added 0.2%. Direxion Daily Financial Bull 3X Shares (FAS) advanced 0.5%, and its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), declined 0.4%. Commodities Crude oil rose 0.2%, and the United States Oil Fund (USO) added 0.3%. Natural gas gained 1.3%, and the United States Natural Gas Fund (UNG) was up 1.2%. Gold on Comex gained 0.7%, and the State Street SPDR Gold Shares (GLD) was up 0.4%. Silver rose 0.5%, and iShares Silver Trust (SLV) gained 0.3%. Consumer The State Street Consumer Staples Select Sector SPDR (XLP) was 1% higher, and the Vanguard Consumer Staples ETF (VDC) rose 1.1%. The State Street Consumer Discretionary Select Sector SPDR (XLY) added 1.1%. VanEck Retail ETF (RTH) was up 1%, and the State Street SPDR S&P Retail (XRT) edged up 0.3%. Healthcare The State Street Health Care Select Sector SPDR (XLV) slipped 0.1%, while iShares US Healthcare (IYH) shed 0.2%, and Vanguard Health Care ETF (VHT) fell 0.4%. IShares Biotechnology ETF (IBB) declined 2.1%. Industrial The State Street Industrial Select Sector SPDR (XLI) added 1.2%. Vanguard Industrials Index Fund (VIS) rose 1.1%, and iShares US Industrials (IYJ) gained 1.1%. Cryptocurrency In midday activity, bitcoin (BTC-USD) shed
BUZZ - Jefferies raises target price, Pershing Square shares surge
October 6th - Alternative asset management company Pershing Square (PS.N) shares rose 7.49% to $58.98. Jefferies raised its target price from $38 to $58 and maintained a "Hold" rating, stating that performance-based fees are expected to continue rising next year. According to data compiled by London Stock Exchange Group (LSEG), 9 out of 10 brokers give the stock a "Buy" or higher rating, and one gives a "Hold" rating; the median target price is $42. The current price-to-earnings ratio is 64.03 times expected earnings per share for the next 12 months, far above the industry median of 10.97 times. As of the previous trading day's close, PS has risen 145.4% since its IPO in April.
Resend-BUZZ-Reports say Venture Global is in negotiations with China over liquefied natural gas sales, and its stock price has surged in response.
Correction of company name spelling in the headline October 6 - Venture Global (VG.N), a liquefied natural gas producer, saw its share price rise by 2.3% to $13.77. According to Bloomberg, disruptions in global transportation caused by the situation in Iran have prompted China to seek diversified supply sources, and Venture Global is in talks to sell liquefied natural gas to more Chinese buyers (link). Venture Global has not immediately responded to a request for comment from Reuters. Bloomberg (link) reported that Venture Global has held preliminary negotiations on long-term contracts with at least three Chinese LNG importers. Out of 18 brokerages, 11 have rated the stock as "buy" or higher, and 7 have rated it as "hold". The median target price is $16. Including intraday fluctuations, VG’s share price has more than doubled so far this year. (For the convenience of non-native English speakers, Reuters provides automated translations of its reports into several other languages. As automated translations may contain errors or fail to convey the desired context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely to assist readers. Reuters accepts no responsibility for any damages or losses caused by the use of automated translation functions.)
Crypto prices
More
